Elekta Valuation
Is EKTABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EKTABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EKTABS (SEK69.88) is trading below our estimate of fair value (SEK130.38)
Significantly Below Fair Value: EKTABS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EKTABS?
Key metric: As EKTABS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is EKTABS's PE Ratio? | |
|---|---|
| PE Ratio | 21.7x |
| Earnings | SEK 1.13b |
| Market Cap | SEK 24.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 12.5x |
| PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does EKTABS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.4x | ||
SN. Smith & Nephew | 35.3x | 22.5% | UK£8.6b |
NIOX NIOX Group | 22.6x | 17.1% | UK£249.1m |
EKF EKF Diagnostics Holdings | 24x | n/a | UK£114.6m |
CTEC ConvaTec Group | 39.7x | 20.5% | UK£4.9b |
EKTABS Elekta | 21.7x | 17.9% | SEK 24.6b |
Price-To-Earnings vs Peers: EKTABS is good value based on its Price-To-Earnings Ratio (21.7x) compared to the peer average (30.5x).
Price to Earnings Ratio vs Industry
How does EKTABS's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: EKTABS is good value based on its Price-To-Earnings Ratio (21.7x) compared to the European Medical Equipment industry average (29.5x).
Price to Earnings Ratio vs Fair Ratio
What is EKTABS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EKTABS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$94.5b
Operates as a health benefits company in the United States.
0HG8
US$401.36
7D
1.7%
1Y
-16.0%
Centene
US$31.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$60.77
7D
3.9%
1Y
-17.3%
Patterson Companies
US$1.9b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
0KGB
US$21.06
7D
-0.8%
1Y
-32.9%